HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
05 2019
Historique:
received: 20 08 2018
accepted: 23 11 2018
pubmed: 14 12 2018
medline: 21 5 2020
entrez: 8 12 2018
Statut: ppublish

Résumé

Second allogeneic hematopoietic stem cell transplantation is a curative treatment option for patients with hematologic malignancies. However, it is unclear whether HLA discrepancy between graft and first donor has an impact on the outcome of second transplantation. We retrospectively analyzed 646 patients receiving second transplantation after an initial HLA mismatched transplantation. With regard to graft-

Identifiants

pubmed: 30523056
pii: haematol.2018.204438
doi: 10.3324/haematol.2018.204438
pmc: PMC6518881
doi:

Substances chimiques

HLA Antigens 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1055-1061

Informations de copyright

Copyright© 2019 Ferrata Storti Foundation.

Références

Bone Marrow Transplant. 2015 Dec;50(12):1508-12
pubmed: 26389832
J Clin Invest. 2002 May;109(10):1335-44
pubmed: 12021249
Nat Med. 2011 Nov 29;18(1):135-42
pubmed: 22127134
Bone Marrow Transplant. 2016 Feb;51(2):186-93
pubmed: 26437057
Int J Hematol. 2007 Oct;86(3):269-74
pubmed: 17988995
Stat Med. 1999 Mar 30;18(6):695-706
pubmed: 10204198
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Bone Marrow Transplant. 2015 Jun;50(6):790-4
pubmed: 25751644
Science. 1999 Jul 16;285(5426):412-5
pubmed: 10411505
J Clin Oncol. 2001 Aug 15;19(16):3675-84
pubmed: 11504749
Nat Med. 2002 Jun;8(6):575-81
pubmed: 12042807
Nat Med. 2005 Nov;11(11):1244-9
pubmed: 16227991
J Clin Invest. 2003 Dec;112(12):1880-6
pubmed: 14679183
Bone Marrow Transplant. 2015 Dec;50(12):1542-50
pubmed: 26367221
Biol Blood Marrow Transplant. 2016 Mar;22(3):584-8
pubmed: 26631751
Haematologica. 2004 Oct;89(10):1238-47
pubmed: 15477210
Semin Hematol. 1991 Jul;28(3):250-9
pubmed: 1887253
Bone Marrow Transplant. 2008 Dec;42(12):783-9
pubmed: 18724393
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Immunol. 2004 Jun 15;172(12):7393-8
pubmed: 15187116
Int J Hematol. 2016 Jan;103(1):11-9
pubmed: 26588927
Int J Hematol. 2016 Jan;103(1):3-10
pubmed: 26547570
Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8
pubmed: 25316109
J Clin Oncol. 2013 Sep 10;31(26):3259-71
pubmed: 23918951
Bone Marrow Transplant. 2004 Oct;34(8):721-7
pubmed: 15322568

Auteurs

Yoshinobu Maeda (Y)

Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences yosmaeda@md.okayama-u.ac.jp.

Tomotaka Ugai (T)

Division of Cancer Epidemiology and Prevention, Department of Preventive Medicine, Aichi Cancer Center Research Institute, Nagoya.
Division of Hematology, Saitama Medical Center, Jichi Medical University, Tochigi.

Eisei Kondo (E)

Division of Hematology, Department of Medicine, Kawasaki Medical School, Okayama.

Kazuhiro Ikegame (K)

Division of Hematology, Department of Internal Medicine, Hyogo Medical College.

Makoto Murata (M)

Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.

Naoyuki Uchida (N)

Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo.

Toshihiro Miyamoto (T)

Hematology, Oncology & Cardiovascular medicine, Kyushu University Hospital, Fukuoka.

Satoshi Takahashi (S)

Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo.

Kazuteru Ohashi (K)

Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo.

Hirohisa Nakamae (H)

Department of Hematology, Osaka City University Hospital.

Takahiro Fukuda (T)

Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo.

Makoto Onizuka (M)

Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa.

Tetsuya Eto (T)

Department of Hematology, Hamanomachi Hospital, Fukuoka.

Shuichi Ota (S)

Department of Hematology, Sapporo Hokuyu Hospital, Hokkaido.

Makoto Hirokawa (M)

Department of General Internal Medicine and Clinical Laboratory Medicine, Akita University Graduate School of Medicine.

Tatsuo Ichinohe (T)

Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University.

Yoshiko Atsuta (Y)

Department of Healthcare Administration, Nagoya University Graduate School of Medicine.

Yoshinobu Kanda (Y)

Division of Hematology, Saitama Medical Center, Jichi Medical University, Tochigi.
Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi.

Junya Kanda (J)

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH